Upstream Bio

Historical price data

Upstream Bio is a clinical-stage biotechnology company focused on developing verekitug, a first-in-class monoclonal antibody antagonist of the TSLP receptor, for major inflammatory respiratory diseases. The company has completed Phase 2 trials in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, with an ongoing Phase 2 trial in chronic obstructive pulmonary disease (COPD). Its strategy is predicated on disrupting a key upstream inflammatory mediator to potentially achieve broader efficacy and a more convenient dosing regimen than existing biologics, aiming to capture significant share in large, underserved markets.

Platform centered on inhibiting the thymic stromal lymphopoietin (TSLP) receptor, an upstream master switch that initiates multiple inflammatory pathways in response to environmental triggers in respiratory diseases.